A PROSPECTIVE OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF TOPIRAMATE ALONE VERSUS TOPIRAMATE WITH VITAMIN D IN PROPHYLACTIC TREATMENT OF PATIENTS WITH MIGRAINE

ALOK DIXIT; MANIK BRAHEMI; NASREEN FATMA KHAN; RAMAKANT YADAV; C. V. SINGH

doi:10.22159/ijpps.2025v17i3.53449

Authors

ALOK DIXIT Department of Pharmacology, Uttar Pradesh University of Medical Sciences, Saifai, Etawah. UP-206130, India
MANIK BRAHEMI Department of Pharmacology, GMC, Budaun-243601, Uttar Pradesh, India
NASREEN FATMA KHAN Department of Pharmacology, GSVM MC, Kanpur. UP-208002, India https://orcid.org/0009-0001-2073-2212
RAMAKANT YADAV Department of Neurology, University of Medical Sciences, Saifai, Etawah-206130, Uttar Pradesh, India https://orcid.org/0000-0002-7787-0771
C. V. SINGH Department of Pharmacology, Uttar Pradesh University of Medical Sciences, Saifai, Etawah. UP-206130, India https://orcid.org/0000-0003-3248-7610

DOI:

https://doi.org/10.22159/ijpps.2025v17i3.53449

Keywords:

Pain severity, VAS, MIDAS, MIGSEV

Abstract

Objective: Migraine affects 10% of the global population, especially women aged 25-55, causing severe headaches with light and sound sensitivity. While acute treatments are common, preventive therapies are underutilized. Recent studies suggest combining vitamin D with Topiramate, an anticonvulsant, could enhance prevention, reducing both attack frequency and duration. Therefore, the present study compares the safety and efficacy of Topiramate alone versus topiramate with Vitamin D.

Methods: A study was conducted on 100 migraine patients to compare the effect of topiramate alone versus topiramate with vitamin D. Pain severity and disability were measured using a Visual Analog Scale (VAS), Migraine Disability Assessment Score (MIDAS), and Migraine Severity (MIGSEV) scores over 12 weeks, excluding patients with other medical conditions.

Results: Both the Topiramate and Topiramate with Vitamin D groups showed significant reductions in VAS, MIDAS, and MIGSEV scores after 12 weeks. Migraine without aura was more common in both groups. The Topiramate with Vitamin D group also experienced increased serum calcium and vitamin D levels. Also, the addition of Vitamin D resulted in greater improvements in pain and disability. This study of 100 migraine patients compared Topiramate alone versus Topiramate with Vitamin D. Most participants were aged 26-40, with a higher prevalence in females. Both groups showed significant improvements in pain and disability, with the Topiramate + Vitamin D group showing better results.

Conclusion: Combining topiramate with vitamin D effectively reduces migraine frequency and disability.

Objective: Migraine affects 10% of the global population, especially women aged 25-55, causing severe headaches with light and sound sensitivity. While acute treatments are common, preventive therapies are underutilized. Recent studies suggest combining vitamin D with Topiramate, an anticonvulsant, could enhance prevention, reducing both attack frequency and duration. Therefore, the present study compares the safety and efficacy of Topiramate alone versus topiramate with Vitamin D.

Methods: A study was conducted on 100 migraine patients to compare the effect of topiramate alone versus topiramate with vitamin D. Pain severity and disability were measured using a Visual Analog Scale (VAS), Migraine Disability Assessment Score (MIDAS), and Migraine Severity (MIGSEV) scores over 12 weeks, excluding patients with other medical conditions.

Results: Both the Topiramate and Topiramate with Vitamin D groups showed significant reductions in VAS, MIDAS, and MIGSEV scores after 12 weeks. Migraine without aura was more common in both groups. The Topiramate with Vitamin D group also experienced increased serum calcium and vitamin D levels. Also, the addition of Vitamin D resulted in greater improvements in pain and disability. This study of 100 migraine patients compared Topiramate alone versus Topiramate with Vitamin D. Most participants were aged 26-40, with a higher prevalence in females. Both groups showed significant improvements in pain and disability, with the Topiramate + Vitamin D group showing better results.

Conclusion: Combining topiramate with vitamin D effectively reduces migraine frequency and disability.

Downloads

Download data is not yet available.

References

O B, A D, B KL. A complete review of migraine. Asian J Pharm Clin Res. 2017 Oct;10(10):57-62. doi: 10.22159/ajpcr.2017.v10i10.19207.

Pietrobon D. Insights into migraine mechanisms and CaV2.1 calcium channel function from mouse models of familial hemiplegic migraine. J Physiol. 2010;588(Pt 11):1871-8.

Nattagh-Eshtivani E, Sani MA, Dahri M, Ghalichi F, Ghavami A, Arjang P, Tarighat-Esfanjani A. The role of nutrients in the pathogenesis and treatment of migraine headaches: review. Biomed Pharmacother. 2018;102:317-25.

Mulder EJ, Van Baal C, Gaist D, Kallela M, Kaprio J, Svensson DA, Nyholt DR, Martin NG, MacGregor AJ, Cherkas LF, et al. Genetic and environmental influences on migraine: a twin study across six countries. Twin Res. 2003;6(5):422-31.

Sangermani R, Boncimino A. The use of nutraceutics in children’s and adolescents’ headaches. Neurol Sci. 2017;38(Suppl 1):121-4.

Evers S. Treatment of migraine with prophylactic drugs. Expert Opin Pharmacother. 2008;9(15):2565-73.

Silberstein SD. Migraine. Lancet. 2004;363(9406):381-91.

Lukacs M, Tajti J, Fulop F, Toldi J, Edvinsson L, Vecsei L. Migraine, neurogenic inflammation, drug development – pharmacochemical aspects. Curr Med Chem. 2017;24(36):3649-65.

Eyles DW, Burne TH, McGrath JJ. Vitamin D, effects on brain development, adult brain function, and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol. 2013;34:47-64.

Wu Z, Malihi Z, Stewart AW, Lawes CM, Scragg R. The association between vitamin D concentration and pain: a systematic review and meta-analysis. Public Health Nutr. 2018;21(11):2022-37.

Nagata E, Fujii N, Hosomichi K, et al. Possible association between dysfunction of vitamin D binding protein (GC Globulin) and migraine attacks. PLoS One. 2014;9(8):e105319.

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-30.

Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol. 2014;2(1):76-89.

Prakash S, Kumar M, Belani P, Susvirkar A, Ahuja S. Interrelationships between chronic tension-type headache, musculoskeletal pain, and vitamin D deficiency: is osteomalacia responsible for both headache and musculoskeletal pain? Ann Indian Acad Neurol. 2013;16(4):650-8.

Garcion E, Sindji L, Nataf S, Brachet P, Darcy F, Montero-Menei CN. Treatment of experimental autoimmune encephalomyelitis in rats by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system. Acta Neuropathol. 2003;105(5):438-48.

Messlinger K, Lennerz JK, Eberhardt M, Fischer MJ. CGRP and NO in the trigeminal system: mechanisms and role in headache generation. Headache. 2012;52(9):1411-27.

Minton GC, Miller AD, Bookstaver PB, Love BL. Topiramate: safety and efficacy of its use in the prevention and treatment of migraine. J Cent Nerv Syst Dis. 2011;3:1-8.

Theeler BJ, Kenney K, Prokhorenko OA, Fideli US, Campbell W, Erickson JC. Headache triggers in the US military. Headache. 2010;50(5):790-4.

Somerville BW. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology. 1972;22(4):355-65.

Victor TW, Hu X, Campbell J, White RE, Buse DC, Lipton RB. Association between migraine, anxiety, and depression. Cephalalgia. 2010;30(5):567-75.

Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, et al. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954-76.

Russell MB, et al. Migraine without aura and migraine with aura are distinct clinical entities: a study of four hundred and eighty-four male and female migraineurs from the general population. Cephalalgia. 1996;16(4):239-45.

Stang PE, et al. Headache, cerebrovascular symptoms, and stroke: the atherosclerosis risk in communities study. Neurology. 2005;64(9):1573-7.

Silberstein SD, et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther. 2006;28(7):1002-11.

Moras K, Nischal H. Impact of amitriptyline on migraine disability assessment score. J Clin Diagn Res. 2014;8(9):KC01-2.

Dwajani S, Ugargol AP. Assessment of quality of life in patients with migraine receiving topiramate. Indian J Pharm Pharmacol. 2014;1(1):30-4.

Laghari MJ, Qazi N, Jamali S, Mustafa G. Role of topiramate in improving quality of life in migraine sufferers versus gold standard propranolol. JLUMHS. 2012;11(1):11-4.

El Hasnaoui A, Vray M, Richard A, Nachit-Ouinekh F, Boureau F; MIGSEV Group. Assessing the severity of migraine: development of the MIGSEV scale. Headache. 2003;43(6):628-35.